Parenteral Drugs (India) Limited

PDPL

INE904D01019

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 03:30:51 21/08/2023 pm IST			5-day change	1st Jan Change
3.39 ^INR	+4.63%		-.--%	-.--%

2023	PSBs Reportedly Shelve Deal to Sell Drug Company Loans to NARCL	CI
2023	NARCL Reportedly Offers to Buy INR 11,000 million Loans of Parenteral Drugs	CI

Parenteral Drugs India Limited Reports Earnings Results for the First Quarter Ended June 30, 2019

August 06, 2019 at 11:23 am IST

Parenteral Drugs India Limited announced earnings results for the first quarter ended June 30, 2019. For the first quarter, the company announced total revenue was INR 87.290 million compared to INR 492.480 million a year ago. Net loss was INR 276.861 million compared to INR 245.785 million a year ago. Basic loss per share was INR 9.29 compared to INR 8.24 a year ago.

Latest news about Parenteral Drugs (India) Limited

PSBs Reportedly Shelve Deal to Sell Drug Company Loans to NARCL	04/23/04	CI
NARCL Reportedly Offers to Buy INR 11,000 million Loans of Parenteral Drugs	11/23/11	CI
Parenteral Drugs Limited Announces Resignation of Pooja Choukse as Company Secretary	10/22/10	CI
Parenteral Drugs Limited Announces Director Changes	09/22/09	CI
Parenteral Drugs Limited Appoints Smt. Chhaya Gupta as an Independent Director	01/22/01	CI
Parenteral Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/22/14	CI
Parenteral Drugs Limited Announces Change in Directorate	02/22/02	CI
Parenteral Drugs Limited Announces Executive Changes	02/22/02	CI
Parenteral Drugs Limited Announces Change in Terms of One Time Loan Settlement Proposal	06/22/06	CI
Parenteral Drugs Limited Announces Resignation of Suruchi Maheshwari as Company Secretary and Compliance Officer	01/22/01	CI
Parenteral Drugs Limited Announces Resignation of Deepali Garhewal as Director	30/21/30	CI
Parenteral Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	12/21/12	CI
Parenteral Drugs India Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	10/21/10	CI
Parenteral Drugs India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	30/21/30	CI
Parenteral Drugs Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	12/21/12	CI
Parenteral Drugs Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	10/20/10	CI
Parenteral Drugs India Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	25/20/25	CI
Parenteral Drugs India Limited Reports Earnings Results for the Third Quarter Ended December 31, 2019	12/20/12	CI
Parenteral Drugs Limited Reports Unaudited Standalone and Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2019	13/19/13	CI
Parenteral Drugs India Limited Reports Earnings Results for the First Quarter Ended June 30, 2019	06/19/06	CI
Parenteral Drugs Limited Announces Disqualification Vinod Kumar Gupta as Director	11/19/11	CI
Parenteral Drugs India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2019	30/19/30	CI
Parenteral Drugs Limited Appoints Vinod Kumar Gupta as Chief Financial Officer	23/19/23	CI
Parenteral Drugs Limited Announces the Resignation of Mr. Balkrishna Vinayak Chaubal from the Post of Nominee Director	20/19/20	CI
Parenteral Drugs Limited Announces Cessation of Vinod Kumar Gupta as Managing Director	27/19/27	CI

Chart Parenteral Drugs (India) Limited

Duration

Period

More charts

Company Profile

Parenteral Drugs (India) Limited is engaged in the manufacturing of pharmaceutical products. It also manufactures intravenous (IV) infusion, inhalation, and veterinary infusion. It offers products in various categories, including IV fluids, oncology, anesthesia and exports. Its IV Fluids include Carbohydrated and Electrolytes, such as Dextrose IP 5%, 10%, 20%, Dextrose IP 25% , and Ringer Lactate IP; Diuretics, such as Mannitol 10%, 20% and Manidex (Mannitol 10% with Glycerine 10%); Dialysis and Irrigation Solution, such as Peritoneal Dialysis Solution with 1.7% Dextrose and 1.5% Glycine; Anti-infective and Anti-fungal, such as Ciprofloxacin 200mg and Metronidazole 500mg and others , such as Tamolgan (Paracetamol 1000mg) and PD-Invert (10% Invert Sugar). Its Oncology product mix includes 5 FU-PAR and BAZIPAR. Its Anesthesia product mix includes Sevoplan (Sevoflurane 100/250ml) and Isoplan (Isoflurane 100/250ml).

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PARENTERAL DRUGS (INDIA) LIMITED	-.--%	1.21M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+31.77%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+14.36%	240B
NOVARTIS AG	+9.19%	210B
ROCHE HOLDING AG	-5.07%	206B
AMGEN INC.	+6.17%	164B

Other Pharmaceuticals